A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)
Part of paid clinical trials in Indianapolis, Indiana.
- Sponsor
- Agios Pharmaceuticals, Inc.
- Study ID
- NCT07656415
- Phase
- PHASE3
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 12 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Mitapivat Matched Placebo — DRUGTablets
- Mitapivat — DRUGTablets
Study Details
The primary objective of this study is to determine the effect of mitapivat versus placebo on the need for transfusions in subjects with SCD.
Key Dates
- First listed
- Jun 18, 2026
- Start date
- Jul 21, 2026
- Status verified
- Aug 2026
- Primary completion
- Aug 31, 2029
- Completion
- Aug 31, 2030
Study Design
- Enrollment
- 159 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: MitapivatSubjects will receive oral mitapivat 100 milligrams (mg), twice daily (BID), for up to 52 Weeks during the double blind (DB) period. Subjects who will complete the DB period may continue receiving mitapivat for up to 52 weeks in the open-label extension (OLE) period.
- Placebo Comparator: PlaceboSubjects will receive oral mitapivat matching placebo, BID, for up to 52 weeks during the DB period. Subjects who will complete the DB period may continue to receive mitapivat for up to 52 weeks in the OLE period.
Primary Outcome Measure
Percentage of Subjects who are Transfusion Free From Week 4 Through Week 52 [ Time Frame: Week 4 through Week 52 ]
Central Contacts
- Agios Medical Affairs08332288474
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Indiana Hemophilia & Thrombosis Center | Indianapolis | Indiana | 46260 | - |
| The Cancer and Hematology Centers (CHC) | Grand Rapids | Michigan | 49503 | - |
| Southern Specialty Clinic | Flowood | Mississippi | 39232 | - |
Find similar trials in Indianapolis, IN
Nationwide
By condition
Related Studies
- ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic DisordersRecruiting · American Thrombosis and Hemostasis Network · Phoenix, Arizona
- A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCDPHASE2/PHASE3 · Recruiting · Pfizer · Mobile, Alabama
- Peer Support for Adolescents and Emerging Adults With Sickle Cell PainRecruiting · University of Pittsburgh · Mobile, Alabama
- A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)PHASE3 · Recruiting · Novartis Pharmaceuticals · Birmingham, Alabama